Company Name or Ticker Symbol
Search for other Categories
Artemis Therapeutics, Inc.  (INKS)
Other Ticker:  
    Sector  Healthcare    Industry Biotechnology & Drugs
   Industry Biotechnology & Drugs
   Sector  Healthcare
Price: $0.0000 $0.00 %
Day's High: 0.00 Week Perf:
Day's Low: $ 0.00 30 Day Perf:
Volume (M): 0 52 Wk High: $ 0.00
Volume (M$): $ 0 52 Wk Avg: $0.00
Open: $0.00 52 Wk Low: $0.00

 Market Capitalization (Millions $) -
 Shares Outstanding (Millions) 5
 Employees 1
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) 0
 Cash Flow (TTM) (Millions $) -0
 Capital Exp. (TTM) (Millions $) 0

Artemis Therapeutics, Inc.
We are a biopharmaceutical company dedicated to the development of novel, safe, and effective agents for the prevention and treatment of severe and potentially life-threatening infectious diseases. Our lead product candidate, artemisone, is a clinical-stage synthetic artemisinin derivative with antiviral and antiparasitic properties. While artemisone is a clinical stage compound, as a result of prior development by third-parties, the Company’s development of artemisone for its proposed indications is in the pre-clinical phase. We expect to advance artemisone initially as an antiviral agent to address unmet clinical needs in the growing population of immunocompromised patients infected with human cytomegalovirus (HCMV), and other related clinical indications. While artemisone is a known chemical compound, that certain license agreement (the “License Agreement”) by and among the Company, Hadasit Medical Research Services and Development Ltd. (“Hadasit”) and Hong Kong University of Science and Technology R and D Corporation Limited (“RDC”) provides us with the exclusive right to further develop it.

INKS is expected to report next financial results on August 14, 2019.

Capricor Therapeutics, Inc.

Capricor Therapeutics, Inc announced first quarter operating deficit of $-2.557168 millions

Capricor Therapeutics, Inc reported disappointing first quarter, where Sales melted down by -42.38 % to $0.23 millions and company posted loss per share to $-0.08, compare to $-0.14, in the same quarter a year ago.

Dd3 Acquisition Corp.

Dd3 Acquisition Corp announced third quarter operating loss of $-0.112925 millions

In the third quarter Dd3 Acquisition Corp decreased loss of $-0.04 per share compare to $-0.14 a year ago and improved from $-0.09 per share from the previous quarter.

Sales remained unchanged to $0.00 millions from $0.40 millions in the same quarter a year ago and sequentially from $0.00 millions.

Cyclacel Pharmaceuticals, Inc.

Losses Widen but Revenues Unchanged

In the first quarter Cyclacel Pharmaceuticals, Inc increased losses of $-0.14 per share compare to $-0.12 a year ago and eps fell from $0.46 per share from the previous quarter.

Sales remained unchanged to $0.00 millions from $0.00 millions in the same quarter a year ago and sequentially from $0.00 millions.

Audioeye Inc

Losses Widen, Sales very Strong

In the first quarter Audioeye Inc increased losses of $-0.28 per share compare to $-0.01 a year ago and increased losses from $-0.22 per share from the previous quarter.

Sales grew strongly by 72.77 % to $1.99 millions from $1.15 millions in the same quarter a year ago and sequentially Sales advanced by 11.44 % from $1.78 millions.

Fang Holdings Ltd

Fang Holdings Ltd announced forth quarter operating income of $39.803 millions

Weak demand caused increase in losses for the forth quarter, company's loss per share grew at $-1.29 from $0.24 where Sales fell by -31.8 % to $303.02 millions from $444.30 millions a year ago.

You need to upgrade your Flash Player

Major Competitors Stock performance

5 Days Decrease / Increase
• View Complete Report


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production


Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales


Event Calendar

RGPT's Profile

Stock Price

RGPT's Financials

Business Description


Charts & Quotes

RGPT's News


RGPT's Competitors

Customers & Markets

Economic Indicators

RGPT's Growth

Company Segments


Stock Performance

Growth Rates




Financial Strength


Largest Companies

Management Effectivness


At a Glance


Growth Rates



Financial Strength


At a Glance



Sectors & Industries





At a Glance








About us


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.  Free Stock Market News Feeds
   Copyright © 2019 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday Data provided by Barchart and subject to terms of use. To view Intraday Stock Data Java must be installed. Java content may be prohibited by the security software, to see the stock quotes, choose "allow content from this page" option. Stock Price, historical and current end-of-day data provided by eoddata. Intraday data delayed per exchange requirements. S&P/Dow Jones Indices (SM) from Barchart and Eoddata. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071